graphpad prism-v10.2.0 software (GraphPad Software Inc)
GraphPad Software Inc is a verified supplier 
90
Structured Review
GraphPad Software Inc
graphpad prism-v10.2.0 software
Graphpad Prism V10.2.0 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/graphpad+prism-v10%2E2%2E0+software/combined+linear+regression+model+prism+graphpad+v10+2+3/pmc11734372-68-24-24
Average 90 stars, based on 1 article reviews
Graphpad Prism V10.2.0 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/graphpad+prism-v10%2E2%2E0+software/combined+linear+regression+model+prism+graphpad+v10+2+3/pmc11734372-68-24-24
Average 90 stars, based on 1 article reviews
graphpad prism-v10.2.0 software - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Concentration Assay:Article Title: Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma Article Snippet: The drug concentration required to inhibit Article Title: Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. Article Snippet: The drug concentration required to inhibit cell growth by 50% compared to the untreated control (GI50) was Control:Article Title: Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma Article Snippet: The drug concentration required to inhibit Article Title: Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. Article Snippet: The drug concentration required to inhibit cell growth by 50% compared to the untreated control (GI50) was Software:Article Title: Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma Article Snippet: The drug concentration required to inhibit Article Title: Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. Article Snippet: The drug concentration required to inhibit cell growth by 50% compared to the untreated control (GI50) was |